These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 38613907)
21. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455 [TBL] [Abstract][Full Text] [Related]
22. Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience. Narasimhan V; Britto M; Pham T; Warrier S; Naik A; Lynch AC; Michael M; Tie J; Ramsay R; Heriot A Dis Colon Rectum; 2019 Oct; 62(10):1195-1203. PubMed ID: 31490828 [TBL] [Abstract][Full Text] [Related]
24. Mutational profiles and prognostic impact in colorectal and high-grade appendiceal adenocarcinoma with peritoneal metastases. Morgan RB; Dhiman A; Sood D; Ong CT; Wu X; Shergill A; Polite B; Turaga KK; Eng OS J Surg Oncol; 2023 Apr; 127(5):831-840. PubMed ID: 36636792 [TBL] [Abstract][Full Text] [Related]
25. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. Schirripa M; Nappo F; Cremolini C; Salvatore L; Rossini D; Bensi M; Businello G; Pietrantonio F; Randon G; Fucà G; Boccaccino A; Bergamo F; Lonardi S; Dei Tos AP; Fassan M; Loupakis F Clin Colorectal Cancer; 2020 Sep; 19(3):219-225. PubMed ID: 32605718 [TBL] [Abstract][Full Text] [Related]
26. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887 [TBL] [Abstract][Full Text] [Related]
27. Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal metastases from colorectal cancer in the Czech Republic in 2018. Němec L; Novák J; Mužík J; Krejčí D; Tomášek J; Šefr R; Bartoška P; Antoš F; Dytrych P; Hoskovec D; Levý M; Šimša J; Klos D; Neoral Č Klin Onkol; 2021; 34(4):278-282. PubMed ID: 34905928 [TBL] [Abstract][Full Text] [Related]
28. Prognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma. Díez-Alonso M; Mendoza-Moreno F; Gómez-Sanz R; Matías-García B; Ovejero-Merino E; Molina R; Soto-Schütte S; San Juan A; Gutierrez-Calvo A Int J Surg Oncol; 2021; 2021():3946875. PubMed ID: 34557315 [TBL] [Abstract][Full Text] [Related]
29. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes. Rosa F; Galiandro F; Ricci R; Di Miceli D; Quero G; Fiorillo C; Cina C; Alfieri S Langenbecks Arch Surg; 2021 Dec; 406(8):2797-2805. PubMed ID: 34661754 [TBL] [Abstract][Full Text] [Related]
30. Can Elderly Patients with Peritoneal Metastasis Induced by Appendiceal or Colorectal Tumours Benefit from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)? Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X Clin Interv Aging; 2021; 16():559-568. PubMed ID: 33833505 [TBL] [Abstract][Full Text] [Related]
31. KRAS mutation in lung metastases from colorectal cancer: prognostic implications. Ghidini M; Personeni N; Bozzarelli S; Baretti M; Basso G; Bianchi P; Tronconi MC; Pressiani T; Grizzi F; Giordano L; Malesci A; Alloisio M; Laghi L; Santoro A; Rimassa L Cancer Med; 2016 Feb; 5(2):256-64. PubMed ID: 26715198 [TBL] [Abstract][Full Text] [Related]
32. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort. Frøysnes IS; Larsen SG; Spasojevic M; Dueland S; Flatmark K J Surg Oncol; 2016 Aug; 114(2):222-7. PubMed ID: 27173150 [TBL] [Abstract][Full Text] [Related]
33. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181 [TBL] [Abstract][Full Text] [Related]
34. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study. Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495 [TBL] [Abstract][Full Text] [Related]
35. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116 [TBL] [Abstract][Full Text] [Related]
36. Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Sluiter NR; de Cuba EM; Kwakman R; Meijerink WJ; Delis-van Diemen PM; Coupé VM; Beliën JA; Meijer GA; de Hingh IH; te Velde EA Clin Exp Metastasis; 2016 Apr; 33(4):297-307. PubMed ID: 26873137 [TBL] [Abstract][Full Text] [Related]
37. Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study. Solaini L; D'Acapito F; Passardi A; Framarini M; Tauceri F; Di Pietrantonio D; Frassineti GL; Casadei Gardini A; Cucchetti A; Cavaliere D; Ercolani G World J Surg Oncol; 2019 Mar; 17(1):58. PubMed ID: 30917826 [TBL] [Abstract][Full Text] [Related]
38. Retrospective Evaluation of the Prognostic Value of Histological Growth Pattern in Patients with Colorectal Peritoneal Metastases Undergoing Curative-Intent Cytoreductive Surgery. Kamdem L; Asmar AE; Demetter P; Zana IC; Khaled C; Sclafani F; Donckier V; Vermeulen P; Liberale G Ann Surg Oncol; 2024 Jun; 31(6):3778-3784. PubMed ID: 38491312 [TBL] [Abstract][Full Text] [Related]
39. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. Kim HS; Heo JS; Lee J; Lee JY; Lee MY; Lim SH; Lee WY; Kim SH; Park YA; Cho YB; Yun SH; Kim ST; Park JO; Lim HY; Choi YS; Kwon WI; Kim HC; Park YS BMC Cancer; 2016 Feb; 16():120. PubMed ID: 26887348 [TBL] [Abstract][Full Text] [Related]
40. Peritoneal carcinomatosis in colorectal cancer: Defining predictive factors for successful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A pilot study. Mahmoud AM; Ismail YM; Hussien A; Debaky Y; Ahmed IS; Mikhael HSW; Moneer M J Egypt Natl Canc Inst; 2018 Dec; 30(4):143-150. PubMed ID: 30472198 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]